[ Englisch] Can MRD Testing Be Done From Peripheral Blood?

Published on

Topics include: What Is Multiple Myeloma?

Is there any new research on testing and monitoring of multiple myeloma patients? Can minimal residual disease (MRD) testing only be done from the bone marrow? Leading myeloma expert Dr. Elisabet Manasanch, from The University of Texas MD Anderson Cancer Center, discusses current forms of testing and clinical studies on complete single-cell analysis for myeloma. Watch now to learn more.

This is a Patient Empowerment Network program produced by Patient Power in partnership with The University of Texas MD Anderson Cancer Center. We thank AbbVie, Inc., Celgene Corporation, and Sanofi for their support.

View more programs featuring and

Produced in association with and

Transcript

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Andrew Schorr:                     

So, we’re going to start getting a lot of questions. Just so I understand, so the MRD testing today is only from the bone marrow, or can it be done from the peripheral blood, too, Doctor?

Dr. Manasanch:          

That’s a great question. Right now, it’s only from the bone marrow.

Andrew Schorr:                     

Okay. But that may change.

Dr. Manasanch:          

That may change. We, actually, have a study here at MD Anderson that I hope is going to be starting by the end of the year, which is going to be looking at something called the single cell assay, looking at, basically, each myeloma cell in the blood and doing very complete analysis, anomic analysis, something called proteomic analysis, looking at how the different cells are a little bit different. I think that, in the future, we probably will be able to do a blood test. We are not close to it yet. So, I don’t think, as I tell you, MRD, FDA approval for regulatory trials, I think, it will be soon.

MRD testing, for the treatment decisions, soon, sooner rather than later. Maybe a test in the blood, maybe not so soon. So, maybe a few years. 

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Related Programs

Why Is MRD Testing Important for Myeloma Patients?

How can myeloma patients benefit from an MRD test? How do the results impact care? Watch now to learn from myeloma experts Dr. Gareth Morgan and Dr. Mohit Trikha.

Published:

When Should Myeloma Patients Consider MRD Testing?

Where do minimal residual disease (MRD) tests fit in with myeloma care? Tune in to hear Dr. Elisabet Manasanch and Tiffany Richards give expert perspectives on timing and frequency of MRD tests.

Published:

Myeloma Patient Perspective: "MRD Testing Gave Me Peace of Mind"

Cherie Rineker, a myeloma patient, author and blogger shares her experience after having MRD testing.

Published:

Advertisement
tritt unserer Gemeinschaft bei Registrieren Sie sich für Veranstaltungen Lesen Sie unseren neuesten Blog
Advertisement

Page last updated on September 9, 2019